Physician profile
Roberto Borrero
NPI 1093164949
$409.76
in general payments reported to CMS, 2019-2025
10 companies · $97.95 in 2025
The $97.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2023: $60.86 · 2024: $79.70 · 2025: $97.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $80.37 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $64.74 | 2023-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $28.54 | 2024 | |
| Exact Sciences Corporation | $24.39 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $18.64 | 2024 | Otezla, Repatha |
| Medtronic, INC. | $18.23 | 2025 | Inceptiv |
| Boston Scientific Corporation | $17.55 | 2025 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $16.35 | 2019 | |
| Mylan LLC | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Borrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.